Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT1013 SAD in healthy subjects
NCT04783090Phase 1Completed
- Sponsor
- Shaanxi Micot Technology Co., Ltd.
- Start
- Jun 2021
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MT1013 in secondary hyperparathyroidism (SHPT) (6 arms), sponsored by Shaanxi Micot Technology Co., Ltd. Primary endpoint: Safety and Tolerability of MT1013 at 3 months. Started Jun 2021; status: completed.
02
Drugs
MT1013
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT04783090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04783090.